Literature DB >> 23261437

Modulation of Epstein-Barr virus nuclear antigen 2-dependent transcription by protein arginine methyltransferase 5.

Cheng-Der Liu1, Chi-Ping Cheng, Jia-Shih Fang, Ling-Chih Chen, Bo Zhao, Elliott Kieff, Chih-Wen Peng.   

Abstract

Epstein-Barr Virus Nuclear Antigen (EBNA) 2 features an Arginine-Glycine repeat (RG) domain at amino acid positions 335-360, which is a known target for protein arginine methyltransferaser 5 (PRMT5). In this study, we performed protein affinity pull-down assays to demonstrate that endogenous PRMT5 derived from lymphoblastoid cells specifically associated with the protein bait GST-E2 RG. Transfection of a plasmid expressing PRMT5 induced a 2.5- to 3-fold increase in EBNA2-dependent transcription of both the LMP1 promoter in AKATA cells, which contain the EBV genome endogenously, and a Cp-Luc reporter plasmid in BJAB cells, which are EBV negative. Furthermore, we showed that there was a 2-fold enrichment of EBNA2 occupancy in target promoters in the presence of exogenous PRMT5. Taken together, we show that PRMT5 triggers the symmetric dimethylation of EBNA2 RG domain to coordinate with EBNA2-mediated transcription. This modulation suggests that PRMT5 may play a role in latent EBV infection.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23261437      PMCID: PMC4018761          DOI: 10.1016/j.bbrc.2012.12.032

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  22 in total

1.  Epstein-Barr virus nuclear antigen 2 binds via its methylated arginine-glycine repeat to the survival motor neuron protein.

Authors:  Stephanie Barth; Michael Liss; Marc D Voss; Thomas Dobner; Utz Fischer; Gunter Meister; Friedrich A Grässer
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

2.  Negative regulation of transcription by the type II arginine methyltransferase PRMT5.

Authors:  Eric Fabbrizio; Selma El Messaoudi; Jolanta Polanowska; Conception Paul; Jeffry R Cook; Jin-Hyung Lee; Vincent Negre; Mathieu Rousset; Sidney Pestka; Alphonse Le Cam; Claude Sardet
Journal:  EMBO Rep       Date:  2002-07       Impact factor: 8.807

3.  Four EBNA2 domains are important for EBNALP coactivation.

Authors:  Chih-Wen Peng; Bo Zhao; Elliott Kieff
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

4.  EGCG debilitates the persistence of EBV latency by reducing the DNA binding potency of nuclear antigen 1.

Authors:  Ya-Lin Chen; Hsing-Lyn Tsai; Chih-Wen Peng
Journal:  Biochem Biophys Res Commun       Date:  2011-12-27       Impact factor: 3.575

5.  Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes.

Authors:  Sharmistha Pal; Sheethal N Vishwanath; Hediye Erdjument-Bromage; Paul Tempst; Saïd Sif
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

6.  An Epstein-Barr virus-producer line Akata: establishment of the cell line and analysis of viral DNA.

Authors:  K Takada; K Horinouchi; Y Ono; T Aya; T Osato; M Takahashi; S Hayasaka
Journal:  Virus Genes       Date:  1991-04       Impact factor: 2.332

7.  Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma.

Authors:  J Menezes; W Leibold; G Klein; G Clements
Journal:  Biomedicine       Date:  1975-07

8.  Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation.

Authors:  J I Cohen; F Wang; E Kieff
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

9.  Prmt5, which forms distinct homo-oligomers, is a member of the protein-arginine methyltransferase family.

Authors:  J Rho; S Choi; Y R Seong; W K Cho; S H Kim; D S Im
Journal:  J Biol Chem       Date:  2001-01-10       Impact factor: 5.157

10.  EBNA3A association with RBP-Jkappa down-regulates c-myc and Epstein-Barr virus-transformed lymphoblast growth.

Authors:  Andrew Cooper; Eric Johannsen; Seiji Maruo; Ellen Cahir-McFarland; Diego Illanes; David Davidson; Elliott Kieff
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  6 in total

Review 1.  The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond.

Authors:  Nicole Stopa; Jocelyn E Krebs; David Shechter
Journal:  Cell Mol Life Sci       Date:  2015-02-07       Impact factor: 9.261

2.  Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.

Authors:  Lapo Alinari; Kiran V Mahasenan; Fengting Yan; Vrajesh Karkhanis; Ji-Hyun Chung; Emily M Smith; Carl Quinion; Porsha L Smith; Lisa Kim; John T Patton; Rosa Lapalombella; Bo Yu; Yun Wu; Satavisha Roy; Alessandra De Leo; Stefano Pileri; Claudio Agostinelli; Leona Ayers; James E Bradner; Selina Chen-Kiang; Olivier Elemento; Tasneem Motiwala; Sarmila Majumder; John C Byrd; Samson Jacob; Said Sif; Chenglong Li; Robert A Baiocchi
Journal:  Blood       Date:  2015-03-05       Impact factor: 22.113

Review 3.  Histone modifiers at the crossroads of oncolytic and oncogenic viruses.

Authors:  Sara A Murphy; Norman John Mapes; Devika Dua; Balveen Kaur
Journal:  Mol Ther       Date:  2022-02-08       Impact factor: 12.910

4.  PRMT5: A novel regulator of Hepatitis B virus replication and an arginine methylase of HBV core.

Authors:  Barbora Lubyova; Jan Hodek; Ales Zabransky; Hana Prouzova; Martin Hubalek; Ivan Hirsch; Jan Weber
Journal:  PLoS One       Date:  2017-10-24       Impact factor: 3.240

Review 5.  Molecular Basis of Epstein-Barr Virus Latency Establishment and Lytic Reactivation.

Authors:  Takayuki Murata; Atsuko Sugimoto; Tomoki Inagaki; Yusuke Yanagi; Takahiro Watanabe; Yoshitaka Sato; Hiroshi Kimura
Journal:  Viruses       Date:  2021-11-23       Impact factor: 5.048

Review 6.  PRMT5 in gene regulation and hematologic malignancies.

Authors:  Fen Zhu; Lixin Rui
Journal:  Genes Dis       Date:  2019-06-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.